Synergy CHC Corp. last reported quarterly results on May 14, 2026, for Q1 FY2026 (the quarter ended Mar 31, 2026): revenue of $5.5 million (-32.8% year over year) and diluted EPS of -$0.23. It usually reports 44–45 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 44–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
May 14, 2026
44 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
5
-32.8%
|
-3
-393.2%
|
-0.23
-330.0%
|
|
Nov 13, 2025
44 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
8
+12.4%
|
0
-84.0%
|
0.01
-90.9%
|
|
Aug 14, 2025
45 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
8
|
1
|
0.17
|
|
May 15, 2025
45 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
8
|
1
|
0.10
|
|
Dec 6, 2024
67 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
7
|
1
|
0.11
|
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- SNYRQ (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Westbrook, ME
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1562733
- Former names
- Synergy Strips Corp. (until Aug 6, 2015); Oro Capital Corporation, Inc. (until Apr 24, 2014)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.